Trial Search Results

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to come to several visits, which will include sensory testing, physical assessments, and questionnaires.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: LDN
  • Drug: Placebo




Inclusion Criteria:

   - Upper and/or lower extremity CRPS

   - On stable treatment for 3 months

   - CRPS for at least 1 year

   - Meet the Budapest criteria for CRPS at time of the study.

Exclusion Criteria:

   - Any known allergy to naltrexone or naloxone

   - Use of prescription opioid analgesics or illegal opioid use

   - Current of planned pregnancy.

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Aaron Yue, MD